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Abstract 
In this study we report the synthesis, characterization and a thorough biological evaluation 
of twelve organoruthenium–8-hydroxyquinolinato (Ru-hq) complexes. The chosen hqH 
ligands bear various halogen atoms in different positions which enables to study effect of 
the substituents on physico-chemical and biological properties. The determined crystal 
structures of novel complexes expectedly show the cymene ring, a bidentately coordinated 
deprotonated hq and a halide ligand (chlorido or iodido) coordinated to the ruthenium 
central ion. In previous studies the anticancer potential of organoruthenium complex with 
8-hydroxyquinoline ligand clioquinol was well established and we have decided to perform 
an extended biological evaluation (antibacterial and antitumor activity) of the whole series 
of halo-substituted analogs. Beside the cytotoxic potential of studied compounds also the 
effect of two selected complexes (9 and 10) on apoptosis induction in MG-63 and A549 
cells was also studied via externalization of phosphatidylserine at the outer plasma 
membrane leaflet. Both selected complexes that gave best preliminary cytotoxicity results 
contain bromo substituted hq ligands. Apoptosis induction results are in agreement with the 
cell viability assays suggesting the higher and more selective anticancer activity of complex 
10 in comparison to complex 9 on MG-63 cells. 
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1. Introduction 
The development of novel cancer metallodrugs is driven by the complexities of presently 
used chemotherapeutic approaches and several issues that such treatment presents, for 
example intrinsic and acquired resistance and common as well as severe side-effects. Metal 
based scaffolds offer us novel opportunities of drug design in terms of building block 
arrangements and geometries and the possibility of direct metal-target interactions beside 
conventional covalent and supramolecular interactions.[1]  
One of the strategies employed in metal-based drug design is the binding of metal 
fragments to known pharmacophores such as 8-hydroxyquinolines.[2] This class of 
compounds is well known for their wide range of clinical applications ranging from 
antibacterial, antifungal and antiviral agents to disinfectants and antiseptics.[3, 4] These 
compounds and their derivatives are present in a large number of preclinical studies and 
exert promising antiparasitic, antimalarial and anticancer effects.[4-7] Their action is often 
attributed to the interaction with metal species including copper, zinc and iron cations 
which are relatively abundant in biological systems and is often dependent on their 
concentration.[4-7]  
The most successful example of this strategy is the case of antimalarial ferrocene-
quinoline conjugates where its main representative – ferroquine – is the most advanced 
organometallic drug candidate having successfully completed phase II clinical trials.[8-11] 
Conjugation of bioactive molecules to organoruthenium species has previously proven a 
successful strategy for obtaining novel metallodrugs.[1, 12-17] Our group has employed 
this strategy previously in the case of antiviral nucleoside analogues,[18, 19] antibacterial 
quinolones,[20-22] azole antifungal agents,[23] pyrithione[24] and most importantly 8-
hydroxyquinoline agent clioquinol (Figure 1).[25, 26] 
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Figure 1: Clioquinol (cqH) and its organoruthenium complex [η6-p-cymene)Ru(cq)Cl][26]. 
 
Clioquinol (cqH) is one of many 8-hydroxyquinolines used in clinical practice. These 
compounds were first used as broad spectrum antimicrobial agents, however, their use is 
nowadays somewhat limited as disinfecting or antiseptic agents. Clioquinol itself has 
completed phase II clinical trials as prospective agent against Alzheimer’s disease[27] but 
the studies were not continued due to difficulties in large scale synthesis. Both clioquinol 
and other hydroxyquinolines have been used as ligands in the design of metallodrugs due to 
the stability and favorable physico-chemical properties of their coordination 
compounds.[28-30] 
In 2014 our group has reported the synthesis and biological evaluation of the 
organoruthenium-clioquinol complex with the formula [(η6-p-cymene)Ru(clioquinolato)Cl] 
(Figure 1).[26] It was established that the complex induces caspase-dependent cell death 
which is observed at much lower concentrations in leukaemic cell lines than in cell lines of 
solid tumors. Moreover, the complex showed proteasome-independent inhibition of the 
NFκB signaling pathway with no effects on cell-cycle distribution which suggest a mode of 
action altogether different from the free clioquinol ligand itself. Encouraged by the 
promising results and the favorable toxicologic profile of this complex we have performed 
an in-depth investigation of the mode-of-action including the interactions with possible 
molecular targets.[25] We have discovered that the organoruthenium-clioquinol complex is 
a potent inhibitor of the lysosomal cysteine protease cathepsin B, an enzyme involved in 
tumor cell invasion and metastasis. While the complex did not show cytotoxic effects in 
low micromolar concentration range on MCF-10A neoT (breast cancer) and U-87 MG 
(glioma) cell lines which both express high levels of proteolytically active cathepsin B it 
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significantly reduced their ability for extracellular matrix degradation and invasiveness in 
two independent cell-based models.[31]  
Some of the organoruthenium complexes of clioquinol and 5,7-dihalosubstituted 8-
hydroxyquinolines presented here were also studied by the Hartinger group (compounds 2, 
5, 7, 10, 11 in this study).[32] It was found that the leaving halogenido ligand plays a 
contributing role in the toxicity profile and surprisingly the cellular accumulation rates do 
not play a major role in it.[32] The compounds are stable in dmso and aqueous solutions at 
a wide range of pH levels. They readily react with histidine, 9-ethylguanine and guanosine 
5’-monophosphate to form adducts. Interestingly, the complexes do not interact with 
methionine while the presence of cysteine causes the cleavage of the cymene ring. 
Altogether, the compounds displayed very similar toxicities towards the tested cancer cell 
lines (HCT116 colon cancer, NCI-H460 carcinoma, SiHa cervical cancer) with IC50 values 
in the low micromolar range.  
Another study of Malipeddi et al.[33] was recently published involving 
organoruthenium complexes and their antibacterial properties. However, this study in 
absence of structural data proposes incorrect structures of the synthesized complexes (1, 2, 
5) in which the hqH ligand is presumed to be coordinated in a neutral form. The study 
offers no evidence to support this assumption and is contrary to both the expected 
chemistry of hydroxyquinolines as well as the previous findings of Thai et al.,[34] 
Hartinger et al.[32] and ourselves which prove the coordination of the ligands in 
monoanionic form also when the synthesis is carried out in absence of base (though 
resulting in lower yields).  
Herein, we offer a wholesome study of the ruthenium-hydroxyquinolinato system 
which includes the synthetic procedure for reliable and high-yield synthesis of 
organoruthenium 8-hydroxyquinolinato complexes, their physico-chemical characterization 
as well as an extended biological evaluation of a series of organoruthenium–8-
hydroxyquinolinato complexes (four new and eight previously published).  
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Table 1: Ruthenium complexes included in this study. 
 
 
       
X = 
Cl 
1[33, 
34] 2[32-34] 3[34] 4 5[32, 33] / Ru-Cq[26] 
X = 
I 6 
7[32] 8 9 10[32] 11[32] 12[32] 
 
2. Materials and methods 
2.1 Materials 
The ruthenium-cymene precursors (chlorido – P1, iodido – P2), hydroxyquinoline ligands 
and solvents were purchased from Strem chemicals, Sigma-Aldrich and/or Fluorochem and 
were used as received. The solvents used in the spectroscopic study were of spectral grade 
from Tedia Company Inc.. Tris(2,2'-bipyridine)ruthenium dichloride ([Ru(bpy)3]Cl2) and 
1,3-Diphenylisobenzofuran (DPBF) used in singlet oxygen generate (SOG) quantum yield 
detection was purchased from Energy Chemical, China. 
Tissue culture materials were purchased from Corning (Princeton, NJ, USA), 
Dulbecco’s modified Eagle’s medium (DMEM) and TrypLE ™ were purchased from 
Gibco (Gaithersburg, MD, USA), and fetal bovine serum (FBS) was purchased from 
Internegocios (Argentina). Annexin V, fluorescein isothiocyanate (FITC), and propidium 
iodide (PI) were from Invitrogen (Buenos Aires, Argentina). All other chemical were from 
Sigma (St. Louis, MO, USA). The MG-63 and A549 cell lines were purchased from ATCC 
(American Type Culture Collection), 
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2.2 Methods 
Syntheses 
General procedure for the synthesis of complexes 1-12. 
40-80 mg of appropriate ruthenium precursor (P1/P2) was suspended in 30 mL of acetone. 
After 10 min of stirring and gentle heating 2.06 molar equivalents of hydroxyquinoline 
ligand and 1.96 molar equivalents of base (NaOMe or NaOAc·3H2O) were added to the 
reaction mixture and the mixture was stirred overnight at room temperature. The turbid 
solution was filtered over celite to remove the precipitated inorganic salts and concentrated 
to 3-5 mL. The addition of 20 mL of cold n-heptane resulted in yellow-brown precipitates. 
Formation of oily products was avoided by drying solvents with sodium sulfate and 4Å 
molecular sieves if necessary. A common impurity present in precipitates are starting 
ruthenium precursors (indicated by the pale reddish color of the heptane mother solution 
after product precipitation) and unreacted/excess hydroxyquinoline ligands. The products 
can easily be purified by flash chromatography on silica where 3 % and 20 % 
acetone/DCM mixtures are used as eluents for excess ligand and Ru-hq complex 
respectively (Rf for precursor/ligand/complex are 0/0.60-0.70/0.05 and 0.05/0.90/0.50-0.70 
respectively). Crystals suitable for X-ray diffraction were obtained by slow evaporation of a 
CHCl3/heptane solution for 1, 6, 7, and 9 and a CHCl3/MeOH solution for 11. 
Characterization 
Attenuated total reflectance (ATR) infrared spectra were recorded on a Perkin-Elmer 
Spectrum 100 spectrometer. The measurements were made in the range from 4000 cm-1 to 
600 cm-1. Elemental analyses were performed on a Perkin-Elmer 2400 CHN Elemental 
analyzer. X-ray diffraction data were collected on an Oxford Diffraction SuperNova 
diffractometer with a Cu microfocus X-ray source, with mirror optics and an Atlas detector. 
The structures were solved using SIR92.[35] Full-matrix least-squares refinement on the F 
magnitudes with anisotropic displacement factors for all of the non-hydrogen atoms used 
SHELXL.[36] The drawings and the analysis of bond lengths, angles and intermolecular 
interactions were carried out using Mercury and Platon.[37] Hydrogen atoms were placed 
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in geometrically calculated positions and were refined using a riding model. NMR spectra 
were recorded on a Bruker Avance III 500 spectrometer. Fluorescence spectra were 
determined using a Horiba FluoroMax-4 spectrofluorometer and fluorescence quantum 
yields were determined using an integrating sphere with absorbance of samples at their 
respective excitation wavelengths being lower than 0.05. Absorbance of samples in 
fluorescence quantum yields and singlet oxygen generate quantum yield detection were 
determined on a Perkin Elmer E35 spectrophotometer. The crystal structures were 
deposited in the CCDC database and were assigned the following deposition numbers; 
1584336-40. 
2.3 Experimental data 
Spectral data of previously reported compounds (1, 2, 3, 5, 7, 10, 11, 12) are in accordance 
with published data. Measurements are included in the SI. 
 
[η6-p-cymene)Ru(5-bromo-8-hydroxyquinolinato)Cl] (4) 
39.4 mg P1 (0.064 mmol), 30.0 mg 5-bromo-8-hydroxyquinoline (0.133 mmol), 17.1 mg 
NaOAc·3H2O  
(0.126 mmol). Yield: 55.5 (87.3 %). 
1H NMR (500 MHz, Chloroform-d): δ 8.93 (s, 1H), 8.36 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 
8.0 Hz, 1H), 7.44 (d, J = 5.4 Hz, 1H), 6.91 (d, J = 5.4 Hz, 1H), 5.62 (s, 1H), 5.49 (s, 1H), 
5.44 (s, 1H), 5.32 (s, 1H), 2.78 (sept, J = 7.7 Hz, 1H), 2.31 (s, 3H), 1.16 (2d, J = 7.7 Hz, 
6H). 
UV-Vis (λ [nm], ɛ [Lmol-1cm-1], c = 7.0·10-5 mol/L, CH2Cl2): 355 nm (0.2660), 437 nm 
(0.2844). 
Selected IR peaks (cm-1): 1739, 1568, 1495, 1457, 1378, 1357, 1319, 1217, 1203, 818, 
654. 
CHN for C19H19BrClNORu: calcld. C 46.22, H 3.88, N 2.84; exp. C 45.99, H 3.58, N 2.97. 
 
[η6-p-cymene)Ru(5-chloro-8-hydroxyquinolinato)I] (6) 
78.5 mg P2 (0.080 mmol), 30.0 mg 5-chloro-8-hydroxyquinoline (0.165 mmol), 21.4 mg 
NaOMe (0.157 mmol). Yield: 85.0 mg (97.9 %). Compound is slightly hygroscopic. 
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1H NMR (500 MHz, Chloroform-d): δ 8.90 (dd, J = 4.9, 1.2 Hz, 1H), 8.39 (dd, J = 8.6, 1.2 
Hz, 1H), 7.44 (dd, J = 8.6, 4.9 Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 
5.58 – 5.53 (m, 2H), 5.53 – 5.47 (m, 1H), 5.37 (d, J = 5.8 Hz, 1H), 2.96 (p, J = 6.9 Hz, 1H), 
2.44 (s, 3H), 1.25 (d, J = 6.9 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H). 
UV-Vis (λ [nm], ɛ [Lmol-1cm-1], c = 3.5·10-5 mol/L, CH2Cl2): 342 nm (0.1751), 446 nm 
(0.1614). 
Selected IR peaks (cm-1): 1738, 1562, 1455, 1373, 1360, 1320, 815, 773, 747, 676, 624. 
CHN for C19H19ClINORu: calcld. C 42.20, H 3.54, N 2.59; exp. C 42.58, H 3.66, N 2.61. 
 
[η6-p-cymene)Ru(2-methyl-5,7-dichloro-8-hydroxyquinolinato)I] (8) 
40.8 mg P2 (0.042 mmol), 25.5 mg 2-methyl-5,7-dichloro-8-hydroxyquinoline (0.110 
mmol), 14.3 mg NaOAc·3H2O (0.105 mmol). Yield: 40 mg (98.3 %). 
1H NMR (500 MHz, Chloroform-d): δ 8.20 (d, J = 8.6 Hz, 1H), 7.41 (s, 1H), 7.35 (d, J = 
8.6 Hz, 1H), 5.68 (s, 1H), 5.64 (s, 1H), 5.48 (d, J = 5.7 Hz, 1H), 5.21 (d, J = 5.7 Hz, 1H), 
3.13 (s, 3H), 2.87 – 2.76 (m, 1H), 2.60 (s, 3H), 1.19 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.9 Hz, 
3H). 
UV-Vis (λ [nm], ɛ [Lmol-1cm-1], c = 6.8·10-5 mol/L, CH2Cl2): 345 nm (0.2755), 437 nm 
(0.2167). 
Selected IR peaks (cm-1): 1621 1546, 1451, 1426 1360, 881, 828, 778, 758, 704, 665.  
CHN for C20H20Cl2INORu: calcld. C 40.77, H 3.42, N 2.38; exp. C 40.29, H 3.11, N 1.98. 
 
[η6-p-cymene)Ru(5-bromo-8-hydroxyquinolinato)I] (9) 
62.9 mg P2 (0.064 mmol), 30.0 mg 5-bromo-8-hydroxyquinoline (0.133 mmol), 17.1 mg 
NaOAc·3H2O (0.126 mmol). Yield: 70 mg (93 %). 
1H NMR (500 MHz, Chloroform-d): δ 8.86 (dd, J = 5.0, 1.2 Hz, 1H), 8.32 (dd, J = 8.6, 1.2 
Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 5.0 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 
5.52 (2d, J = 6.0 Hz, 2H), 5.48 (d, J = 6.0 Hz, 1H), 5.34 (d, J = 6.0 Hz, 1H), 2.94 (sept, J = 
6.9 Hz, 1H), 2.41 (s, 3H), 1.22 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H). 
UV-Vis (λ [nm], ɛ [Lmol-1cm-1], c = 4.5·10-5 mol/L, CH2Cl2): 341 nm (0.2036), 446 nm 
(0.1923). 
Selected IR peaks (cm-1): 1739, 1562, 1493, 1450, 1357, 1317, 1218, 1205, 820, 645. 
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CHN for C19H19BrINORu: calcld. C 38.99, H 3.27, N 2.39; exp. C 38.73, H 2.97, N 2.62. 
 
Fluorescence measurements 
Table 2: Fluorescent properties of 5 and 11. 
Cpd. Solvent λex λem Фa /% 
5 CH2Cl2 355 424 0.06 
 MeCN 270 409 N.d. b 
MeOH 290 416 N.d. b 
DMSO 360 402 N.d. b 
11 CH2Cl2 350 425 N.d. b 
 MeCN 270 415 N.d. b 
MeOH 270 416 N.d. b 
DMSO 360 424 N.d. b 
a Fluorescent quantum yields are calculated using integrating sphere. b Lower than 0.01 %. 
Singlet oxygen generate (SOG) quantum yield measurement 
DPBF (1,3-Diphenylisobenzofuran, 10 μM) was dissolved in MeCN and its absorption 
spectra were recorded. Ruthenium complexes (10 μM) were then added to the solution and 
absorption spectra were recorded after laser irradiation (450 nm) individually. The 
absorbance at 411 nm (λ411) indicates the DPBF absorption and the differentiation with that 
of unirradiated sample were recorded versus irradiation time. Then the slopes can be 
obtained which stand for the SOG efficiency. The SOG efficiencies can be calculated 
compared to the reference sample tris(2,2'-bipyridine) ruthenium dichloride. 
Cell line and growth conditions 
MG-63 human osteosarcoma cells, A549 human lung adenocarcinoma cells and MRC-5 
human fibroblast were grown in DMEM containing 10 % FBS, 100 U/mL penicillin, and 
100 μg/mL streptomycin at 37° C in a 5 % CO2 atmosphere. Cells were seeded in a 75-cm2 
flask, and when 70–80 % of confluence was reached, cells were subcultured using 1 mL of 
TrypLE ™ per 25-cm2 flask. For experiments, cells were grown in multiwell plates. When 
cells reached the desired confluence, the monolayers were washed with DMEM and were 
incubated under different conditions according to the experiments. 
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Cell viability study: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed according to Mosmann.[38] Briefly, cells were seeded in a 96-well dish, allowed 
to attach for 24 h, and treated with different concentrations of Ru compounds at 37° C for 
1, 3, 6 and 24 h. Afterward, the medium was changed and the cells were incubated with 0.5 
mg/mL MTT under normal culture conditions for 3 h. Cell viability was marked by the 
conversion of the tetrazolium salt MTT to a colored formazan by mitochondrial 
dehydrogenases. Color development was measured spectrophotometrically with a 
microplate reader (model 7530, Cambridge Technology, USA) at 570 nm after cell lysis in 
DMSO (100 μL per well). Cell viability was plotted as the percentage of the control value. 
Measurement of externalization of phosphatidylserine by annexin V–FITC/PI staining 
Cells in early and late stages of apoptosis were detected with annexin V–FITC and PI 
staining. Cells were treated with 10, 25 and 100 μM of Ru complexes and were incubated 
for 3 and 6 h prior to analysis. For the staining, cells were washed with PBS and adjusted to 
a concentration of 1·106 cells per milliliter in 1X binding buffer. To 100 μL of cell 
suspension, 2.5 μL of annexin V–FITC was added and the mixture was incubated for 15 
min at room temperature. Finally, 2 μL PI (250 μg/mL) was added prior to analysis. Cells 
were analyzed using flow cytometer (BD FACS Calibur™) and FlowJo 7.6 software. For 
each analysis, 10,000 counts, gated on a forward scatter versus side scatter dot plot, were 
recorded. Four subpopulations were defined in the dot plot: the undamaged vital (annexin V 
negative/PI negative), the vital mechanically damaged (annexin V negative/PI positive), the 
apoptotic (annexin V positive/PI negative), and the secondary necrotic (annexin V 
positive/PI positive) subpopulations. 
Antibacterial activity 
The in vitro antibacterial activity of the synthesized compounds was carried out using 
Escherichia coli (Gram negative), Bacillus cereus (Gram positive) and Staphylococcus 
Aureus (Gram positive) bacterial strains. The MICs of some synthesized compounds 
against three bacterial strains were evaluated using the micro-broth dilution method using 
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Muller-Hinton broth in tubes. The test compounds were first dissolved in DMSO and then 
diluted with sterile water (0.78-13.6 μg/ml). Bacterial suspension (106 cfu/mL) was then 
added to each tube and the tube set aside for incubation. After incubation for 24 h at 37 °C, 
MICs were measured. Three replicates were performed for each experiment. 
3. Results and discussion 
3.1 Syntheses and characterization 
Previous studies present several different synthetic methods for preparation of ruthenium 
hydroxyquinoline complexes including the two-step synthesis via preparation of the sodium 
hydroxyquinolinato salts or several solvent changes. Here we present a one-step one-pot 
synthesis which is a reliable method of synthesizing the presented compounds. The starting 
reagents all possess sufficient solubility in acetone for the reaction to proceed though at a 
slower rate as generally syntheses were carried overnight. We found that refluxing often 
results in products containing impurities which can however be removed by flash 
chromatography. Room temperature reactions are thus preferred. The syntheses with chloro 
and bromo substituted ligands had excellent conversion rates and good yields but, reactions 
with 5,7-diiodo-8-hydroxyquinoline ligand were proven to be more tedious. While we were 
unable to replicate the synthesis of the organoruthenium-chlorido complex bearing this 
ligand (published by Hartinger et al.[32]) the reaction with the iodido ruthenium dimer 
resulted in moderately pure products only by using sodium acetate as base. Reactions with 
sodium methoxide generally resulted in the formation of at least three hydroxyquinoline 
species as determined by NMR. 
The crystal structures reveal the expected typical piano-stool geometry (Figure 2) 
with the cymene ligand π-bonded to the central ruthenium ion while the remaining three 
coordination sites are occupied by the halido ligand and the N,O-bound hydroxyquinoline 
ligand in its deprotonated state. All bonds and angles are within the expected range of 
values for previously reported structures of compounds 3[32] and 5[32] as well as the 
previously reported structures of the organoruthenium complexes the parent (unsubstituted) 
ligand 8-hydroxyquinoline (8-hqH; Table 3).[32, 39, 40] Detailed crystallographic data is 
given in Table S1. 
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Figure 2: Crystal structures of compounds 1, 6, 7, 9, and 11 with heteroatom labelling. Thermal 
ellipsoids are shown at 40 % probability level. Hydrogen atoms and solvent molecules are omitted 
for better clarity of presentation. 
 
Table 3: Bond lengths and N-Ru-O angle in ruthenium 8-hydroxyquinoline complexes with general 
formula [η6-cymene]Ru(hq)X]; X = Cl, I. 
 Ru-O Ru-N Ru-Cl O-Ru-N 
Ru-Cq; [26] 2.075(3) 2.106(3) 2.427(1) 78.22(12) 
[η6-cymene]Ru(8-hq)Cl]; [40] 2.073(2) 2.094(2) 2.4219(7) 78.80 
[η6-cymene]Ru(8-hq)Cl]; [39] 2.076(2) 2.086(2) 2.4176(7) 78.90 
[η6-cymene]Ru(8-hq)Cl]; [32] 2.077(2) 2.096(2) 2.4245(6) 78.87 
1 2.078(2) 2.093(2) 2.4147(5) 78.82(7) 
3; [32] 2.063(1) 2.145(2) 2.4130(5) 78.55 
5; [32] 2.11(1) 2.08(1) 2.429(3) 78.60 
 Ru-O Ru-N Ru-I O-Ru-N 
6 2.073(2) 2.087(2) 2.7169(3) 78.95(8) 
7 2.075(2) 2.088(3) 2.7262(4) 78.89(10) 
9 2.080(3) 2.069(3) 2.7260(5) 78.47(12) 
11 2.059(7) 2.091(9) 2.7327(11) 78.9(3) 
 
3.2 Luminescence properties of selected ruthenium-hq complexes  
It was previously reported that ruthenium-hydroxyquinolinato complexes exert 
fluorescence properties.[33] We have recorded fluorescence spectra in various solvents 
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(Table 2) and determined quantum yields for selected compounds. Both complexes 5 and 
11 display analogous emission behaviors as previously reported. However, the ruthenium-
hq complexes show inefficient fluorescence and only the quantum yield of complex 5 in 
CH2Cl2 is detectable (higher than 0.01 %). Ruthenium(II) tris-bipyridine (bpy) complex and 
related compounds have been proved to be efficient photosensitizers of singlet oxygen and 
thus utilized as anticancer reagents and we have therefore decided to check if our 
compounds also bear such potential. However, in this case it was established, that two 
selected compounds display negligible singlet oxygen production compared to 
[Ru(bpy)3]2+.[41-43] The low luminescence efficiency and negligible SOG of the two 
complexes (Figure S1) might be ascribed to the non-irradiative decay of excited states or 
the poor excitation efficiency of these organometallic ruthenium complexes, which are 
different from analogues of complex [Ru(bpy)3]2+.[44] Without SOG ability and 
photodynamic therapeutic activity, all these complexes were further investigated for their 
antitumor and antibacterial activity in normal condition without the photo-irradiation.  
3.3 Effect of Ru complexes on cell viability in MG-63 and A549 cells. 
To test the antitumor effect of Ru compounds, human MG-63 osteosarcoma cells and 
human A549 lung adenocarcinoma cells were exposed to the complexes 1, 2, 3, 4, 5, 8, 9, 
10, 11, 12 during 24 h. The alteration in the energetic metabolism of the cells was 
determined by the MTT assay. 
As can be seen in Figure 3, the complexes 1, 2, 4, 5, 8, 9, 10, 11, 12 caused an 
inhibitory effect on both cell lines in the range of 10 to 100 μM whereas the complex 3 only 
shows antiproliferative effects at higher concentration (100 μM). 
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Table 4: IC50 values of ruthenium complexes against MG-63 and A549 cells after 24 h of 
incubation. 
IC50 (µM) MG-63 cells A549 cells 
1 24 ± 4 68 ± 5 
2 15 ± 3 62 ± 3 
3 >100 ± >100 ± 
4 17 ± 2 21 ± 2 
5 8 ± 2 10 ± 1 
8 50 ± 5 45 ± 4 
9 24 ± 4 38 ±5 
10 8 ± 1 19 ±3 
11 49 ± 6 54 ±6 
12 9 ± 2 19 ± 3 
 
 
Figure 3: Effects of ruthenium complexes (1–5, 8–12) on MG-63 human osteosarcoma cell line and 
A549 human lung adenocarcinoma proliferation. Cells were incubated in serum-free Dulbecco’s 
modified Eagle’s medium (DMEM) alone (control) or with different concentrations of ruthenium 
complexes (1–5, 8–12) at 37 °C for 24 h. The results are expressed as the percentage of the basal 
level and represent the mean ± the standard error of the mean (SEM) (n = 18). *significant 
difference in comparison with the basal level (p<0.01) 
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Table 4 shows the IC50 values for ruthenium compounds towards MG-63 and A549 cancer 
cells. As it can be seen ruthenium complexes produced their antitumor effects with the 
following increase of potency: 3<< 8, 11 < 1, 2 < 9 < 4, 12 < 5, 10. 
The results of the present study (Figure 3 and Figure 4) confirm the findings of the 
Hartinger group on the relatively small influence of the halido ligand on the toxicity of the 
organoruthenium-hydroxyquinoline complexes. However, in contrast to that study our 
cytotoxicity assays (though on different cell lines) have shown that the halogen substitution 
pattern on the hq ligand itself does result in major changes in anticancer activity. The 
comparison of the anticancer activities suggests that the bromo substituents in position 5 
and 7 of the quinoline ring play an important role in the antitumor activity of the ruthenium 
compounds (see complexes 5 and 10). On the other hand, the presence of the methyl group 
in position 2 diminished the anticancer activity which proposes that this kind of ligands are 
detrimental for the anticancer activity of ruthenium compounds (see complexes 3 and 8). 
The introduction of iodine instead of chlorine at position 2 improved slightly the anticancer 
activity against osteosarcoma and lung carcinoma cell lines (comparison between complex 
3 and 8). Our recent study on platinum(II)-hydroxyquinolinato complexes shows a very 
similar influence of the halogen-substitution pattern on the anticancer activity as in this 
case where the introduction of the bromo substituents on positions 5 and 7 resulted in 
increased toxicity in three different cell lines while the presence of the methyl substituent 
on position 2 resulted in a marked decrease.[45]  
To determine the selectivity of antitumoral actions of complexes 9 and 10, we performed 
new experiments using normal fibroblast cell line (MRC-5) and we compared its effects by 
calculating the selectivity index (SI). Table 5 shows the higher selectivity of compound 10 
than compound 9 on MG-63 cells. The SI values are 1.9 and 1.3 (MG-63 cells) for 
compounds 9 and 10, respectively. Nevertheless, both compounds did not show selectivity 
actions on A549 cells (SI= 0.8). 
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Table 5: IC50 and SI values of complexes 9 and 10 against MG-63 and A549 cells after 24 h of 
incubation. 
 
IC50 (µM) MG-63 cells A549 cells MRC-5 
cells 
SIMG-63 SIA549 
9 24 ± 4 38 ±5 31± 2 1.3 0.8 
10 8 ± 1 19 ±3 15± 2 1.9 0.8 
 
Taking into consideration the higher antiproliferative action and cytotoxicity of complexes 
9 and 10, than that observed for other ruthenium compounds, we have decided to evaluate 
the antitumor actions of these complexes at lower times of incubation (3 and 6 h). 
3.4 Effect of complexes 9 and 10 on cell viability in MG-63 and A549 cells. 
To obtain deeper insight into the antiproliferative effects of complexes 9 and 10, the 
cytotoxicity of these complexes at lower times was investigated through the reduction of 
MTT assay. In the Figure 4 the effects of complexes 9 and 10 on the cell viability of MG-
63 (A, B) and A549 cells (C, D) is shown. After 3 h, complex 10 impaired cell viability on 
MG-63 cells at 25 and 100 μM whilst the complex 9 only caused inhibitory effects at 100 
μM. After 6 h of incubation, compound 10 provoked higher cytotoxicity than compound 9 
(40 % survival vs 21 % survival). Besides, after 3 and 6 h both compounds increased the 
cytotoxicity levels in the range of 25-100 μM on A549 cells.  
To explore the mode of cell death induced by complexes 9 and 10, in the next step, 
we investigated the activation of apoptosis. 
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Figure 4: Effects of ruthenium complexes (9 and 10) on MG-63 human osteosarcoma cell line (A 
and B) and A549 human lung adenocarcinoma proliferation (C and D). Cells were incubated in 
serum-free Dulbecco’s modified Eagle’s medium (DMEM) alone (control) or with different 
concentrations of ruthenium complexes (9 and 10) at 37 °C for 3 (A, C) and 6 h (B, D). The results 
are expressed as the percentage of the basal level and represent the mean ± the standard error of the 
mean (SEM) (n = 18). *significant difference in comparison with the basal level (p<0.01) 
3.5 Effect of complexes 9 and 10 on apoptosis induction in MG-63 and A549 cells. 
Apoptosis is a physiological process of cell death enhanced in the presence of injurious 
agents. It produces several changes in the cell structure. As a consequence, a genetic 
program that leads to cell death is activated. Apoptosis is characterized by some 
morphological changes in the nucleus and the cytoplasm.[46] One of the first alterations 
that can be defined is the externalization of phosphatidylserine at the outer plasma 
membrane leaflet. Independently of the cell type and the nature of the harmful agent, the 
externalization of phosphatidylserine is always present in the earlier apoptotic events. 
Annexin V–FITC is a fluorescent probe with high affinity for phosphatidylserine, allowing 
its determination by fluorescence assays. 
Figure 5 and Figure 6 depict the flow cytometry results of the apoptotic process in 
the presence of complexes 9 and 10 (10, 25 and 100 μM) after 3 and 6 h of incubation in 
MG-63 and A549 cells respectively. 
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Figure 5: Effect of complexes 9 and 10 on the programmed cell death using flow cytometry in MG-
63 cells. The cells were incubated with 10, 25 and 100 μM of the complex 9 during 3 (A) and 6 (B) 
h and complex 10 after 3 (C) and 6 (D) h. Plots are representative of three independent experiments. 
For each analysis 10,000 counts, gated on a FSC vs SSC dot plot, were recorded. Graphical bars 
show the percentage of Annexin V(+), V(+)/PI(+) and V(-)/PI(+) cells. Results are expressed as the 
mean ± SEM, n = 9, *significant differences vs. control (p < 0.01).  
 
Figure 5A and Figure 5C show that after 3h of incubation of MG-63 cells, the control 
cultures showed 3 % of necrotic cells were annexin V negative / PI positive whilst the 
treatment with complexes 9 and 10 showed 24 % and 42% of necrotic cells at 100 μM, 
respectively. These results changed at 6 h (Figure 5B and Figure 5D), showing a 
substantial increase in the necrotic cellular fraction. After 6 h of treatment, complex 9 
resulted in approximately 54 % of necrotic cells and complex 10 caused about 64 % of 
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necrotic cells suggesting that complex 10 has stronger antitumor effects than complex 9 on 
human osteosarcoma cells. As it can be seen, the percentages of apoptotic and 
apoptotic/necrotic cells increased with the concentration of both complexes and the 
exposure time. These results are in accordance with the viability assays (see Figure 4), 
confirming that the deleterious action of both complexes is dependent on their 
concentration. 
On the other hand, Figure 6A and Figure 6C show that after 3 h of incubation of 
A549 cells, the basal condition showed 2 % of early apoptotic cells annexin V(+)/PI(-) and 
1 % of late apoptotic cells annexin V(+)/PI(+) while after 3 h of incubation, complex 9 
increased the levels of early apoptotic cells and late apoptotic cells (12 and 4 %, 
respectively) and the complex 10 showed 8 % of annexin V(+)/PI(-) and 5 % of annexin 
V(+)/PI(+), respectively. 
After 6 h of treatment (Figure 6B and Figure 6D), complex 9 resulted in 76 % of 
early apoptotic cells and produced a striking increase in this fraction of apoptotic cells (16 
%) whilst the compound 10 increased the level of early apoptotic cells annexin V(+)/PI(-) 
and late apoptotic cells annexin V(+)/PI(+) (20 % and 40 %, respectively) on A549 cells. 
These results are in agreement with the cell viability assays (Figure 4) suggesting the 
higher anticancer activity of complex 10 in comparison to complex 9. 
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Figure 6: Effect of complexes 9 and 10 on the programmed cell death using flow cytometry in 
A549 cells. The cells were incubated with 10, 25 and 100 μM of the complex 9 during 3 (A) and 6 
(B) h and complex 10 after 3 (C) and 6 (D) h. Plots are representative of three independent 
experiments. For each analysis 10,000 counts, gated on a FSC vs SSC dot plot, were recorded. 
Graphical bars show the percentage of Annexin V(+),V(+)/PI(+) and V(-)/PI(+) cells. Results are 
expressed as the mean ± SEM, n = 9, *significant differences vs. control (p < 0.01).  
3.6 Antibacterial activity 
Due to the increasing problem of bacterial resistance to conventional agents, novel 
approaches will be soon necessary. Inclusion of metal fragments in the structures of 
established antibacterial agents can result in synergistic activity either by affecting different 
molecular targets or simply by acting as delivery systems.[47-49] In the case of our 
previous work with ruthenium complexes of quinolone antibacterial agents a loss of 
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antibacterial activity upon coordination to the organoruthenium fragment was observed.[20] 
Thus, we were interested to study if hydroxyquinolines retain their antibacterial activity 
when bound to ruthenium. Additional reason to study antibacterial potential of selected 
compounds is that chemotherapy commonly weakens the immune system. It would be 
desirable that in one compound both activities (anticancer and antibacterial) are 
present.[50] The in vitro antibacterial activity of the complexes 9 and 10 was carried out 
using Escherichia coli, Bacillus cereus and Staphylococcus aureus bacterial strains by 
micro-broth dilution method.  
The results of the antibacterial screening are summarized inTable 6. Both 
compounds tested were found to have moderate antibacterial activity, complex 9 displayed 
strong inhibition action at MIC = 6.25 µg/mL against strains B. cereus and E. coli whilst 
complex 10 exhibited stronger inhibition effects on B. cereus than E. coli (MIC = 6.8 
µg/mL and MIC = 10.2 µg/mL, respectively). Besides, compound 9 showed a slightly 
stronger antibacterial action than compound 10 toward S. aureus (MIC9= 14.6 µg/mL vs 
MIC10= 15.4 µg/mL). In addition, to determine the effectiveness of compounds 9 and 10 as 
antibacterial agents we calculated the selectivity index (SI) considering the IC50 values of 
complex 9 (19 µg/mL ) and 10 (10.2 µg/mL) on normal fibroblast (MRC-5). The SI values 
showed that compound 9 exhibited in vitro antibacterial activities at non-cytotoxic 
concentrations against bacterial strains used in this study. 
In this sense, it seems that the hydrogen atom at C7 plays an important role in the 
antibacterial activities. It is also worth to compare these results with antibacterial activity 
that was determined for some of our previously prepared ruthenium complexes. In our test 
with various Ru(III) compounds, weak activity (250 μg/mL) was only found for mer-
[RuCl3(dmso-S)(phenanthroline)] whereas other tested compounds were not active.[51] In 
another study, antibacterial activity of organoruthenium(II) complex with antibacterial 
quinolone nalidixic acid was determined to be 23.8 μg/mL which is higher from activities 
determined in this paper for complexes 9 and 10.[20] It is clear that many factors govern 
the antibacterial properties of ruthenium complexes (e.g. oxidation state of metal; type of 
ligand, etc) and more data are needed to get a clearer picture.  
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Table 6: The in vitro antibacterial activity as MIC (µg/mL) and SI for compounds 9 and 10. 
 
Compounds E. coli B. cereus S. aureus SI E.coli SI B.cereus SI .S. aureus 
9 6.25 6.25 14.6 3.04 3.04 1.3 
10 10.2 6.8 15.4 1 1.5 0.67 
 
Furthermore, we would like also to mention that both compounds did not exert effects in 
preliminary tests on two fungi strains (Candida albicans and Aspergillus niger) in the 
tested concentration range (2.5 to 100 µM). 
4. Conclusions 
Novel ruthenium compounds as potential therapeutics currently require more intensive 
research to be more successful. Herein we thus present the continuation of our studies on 
organoruthenium-hydroxyquinolinato complexes with the optimization of synthetic 
procedures resulting in reliable and high-yield synthetic pathways, novel structural data for 
five different organoruthenium complexes and extensive biological evaluation of this series 
of compounds. The anticancer and antibacterial effects were investigated in order to 
evaluate the effects of the halogen substitution on positions 5 and 7 of the quinoline ring. 
Compounds were tested using human lung and bone cancer cells and E. coli, B. cereus and 
S. aureus bacterial strains.  
In this order, the antibacterial effect of compound 9 was higher than compound 10 
for all strains. Moreover, compounds 9 and 10 bearing bromo-substituted ligands impaired 
cell viability in a concentration-dependent manner showing stronger antiproliferative 
actions in human osteosarcoma than in lung adenorcarcinoma cells. Nevertheless, the 
antiproliferative action of the complex 10 was more pronounced than compound 9 in bone 
and lung cancer cell lines. Therefore, combining previous knowledge with the in vitro 
anticancer activity screening, mode-of-action assays and determination of the toxicologic 
profile has resulted in the determination of lead compound 10 to be selected as candidate 
for undergoing preclinical in vivo experiments. 
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Herein we present the study of the cytotoxic potential and apoptosis induction of a series of 
organoruthenium 8-hydroxyquinolinato complexes. Bromo substituted ligands gave best 
preliminary cytotoxicity results. Apoptosis induction results are in agreement with the cell 
viability assays. The most toxic compounds displayed IC50 values in the low micromolar 
range.  
Highlights: 
- Synthesis, characterization and biological evaluation of twelve organoruthenium–8-
hydroxyquinolinato (Ru-hq) complexes 
- Investigation of anticancer and antibacterial activity 
- Study of apoptosis induction 
- Incorporation of bromo substituents on ligand is highly beneficial 
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